Highlights

  • Entropy Neurodynamics is developing intravenous psilocin administered alongside psychotherapy.
  • The first Cohort 2 participant completed a 60-minute infusion on 5 October 2026.
  • The new regimen is being evaluated against the 140-minute infusion used in Cohort 1.
  • Cohort 1 reported clinically meaningful improvement across all six participants at 12 weeks.
  • Cohort 2 is fully recruited, with topline findings expected by the end of CY2026.

Entropy Neurodynamics Limited (ASX:ENP) is a clinical-stage biotechnology company developing formulations of psilocin for administration with psychotherapy in neuropsychiatric disorders. Its lead intravenous program, TRP-8803, is designed to allow clinicians to manage the onset, intensity and duration of the psychedelic experience. The company’s October 2026 clinical update centres on whether a shorter infusion can retain those treatment characteristics and the responses observed in its binge eating disorder (BED) study.

Shorter Infusion Tested in Binge Eating Disorder

On 7 October 2026, Entropy Neurodynamics (ASX:ENP) reported that the first participant in Cohort 2 of its Phase 2 BED study had completed a 60-minute TRP-8803 infusion. The participant received treatment on 5 October and was discharged after the required post-treatment clinical assessments. The company also reported that the participant experienced a maximum intensity rating of 9/10 on the study’s qualitative scale. A single observation cannot establish efficacy.

Cohort 2 is testing a shorter administration period than the 140-minute regimen used in Cohort 1. Entropy Neurodynamics (ASX:ENP) is assessing whether the altered regimen preserves controlled delivery and favourable clinical responses across the full cohort. All six participants required for Cohort 2 have been recruited.

What the Initial Patient Results Show

In its September 2026 report, Entropy Neurodynamics (ASX:ENP) described outcomes for six treatment-resistant BED participants in Cohort 1. At 12 weeks, all six met the study’s threshold for clinically meaningful improvement, while three had experienced no binge eating episodes during the 84-day follow-up. The company reported a 73% reduction in weekly binge eating episodes from baseline and a 50% remission rate in this small cohort.

The observed outcomes were reported in a small cohort, and the shortened infusion is being assessed separately. Consequently, Entropy Neurodynamics (ASX:ENP) has not yet demonstrated that the 60-minute schedule delivers comparable long-term clinical responses.

Why Intravenous Administration Matters

TRP-8803 delivers psilocin, the active metabolite of psilocybin, directly by intravenous infusion. Oral psilocybin must be absorbed and metabolised before producing its effects. The company’s delivery approach is intended to offer greater control of drug administration and the timing of the psychedelic experience. Precise control remains a development objective that requires assessment of safety, tolerability and patient outcomes in controlled clinical settings.

Treatment duration is also relevant to the clinical operating model. A shorter supervised session could affect the time required from treatment facilities and healthcare professionals, but those practical benefits depend on the full protocol, observation requirements and eventual clinical findings. Entropy Neurodynamics (ASX:ENP) has not established broader patient throughput or cost outcomes through the first shortened infusion.

Remaining Clinical and Operational Questions

Further Cohort 2 dosing and follow-up will test whether patients receiving the 60-minute regimen experience comparable benefits to those in Cohort 1. The company expects topline results by the end of CY2026. Development-stage uncertainties include limited sample size, safety monitoring and regulatory assessment. These factors separate an early clinical milestone from an approved or commercially available treatment.

Key Insights

The October update documents a completed shortened infusion rather than a definitive clinical outcome. Entropy Neurodynamics (ASX:ENP) is examining whether intravenous delivery can provide a more manageable treatment schedule while retaining clinically meaningful effects. Its existing BED findings and the pending Cohort 2 dataset address different questions: the former concerns early patient responses, while the latter evaluates the feasibility and effects of a shorter infusion.